HTB news: early reports from the international AIDS 2026 conference
1 August 2026. Related: News.
August news – July news – June news – All back issues
Recent HTB highlights
EARLY ACCESS
Review of plenary lecture by leading researcher Raphael Landovitz on the PrEP efficacy, recent UK guidelines and the importance of politics to enable global access.
For the first time in many years, IAS has enabled free open access to the opening ceremony and closing sessions as live webcasts and YouTube videos. These moving and important sessions are free for everyone to be able to watch even if they were not able to be a delegate.
Cure-related research show bNAbs could be as important in chronic HIV as in acute infection with early ART. New biomarkers could predict responders, driven by reduced reservoir diversity rather than reservoir size.
Review on ART pipelines including two oral weekly combinations, access to long-acting injectables, bNAbs and more.
This new report includes data to help track progress to global HIV goals for 2030 – including impact of funding changes in 2025.
Even before the AIDS 2026 conference opens, the online programme shows some of the expected highlights.
This review covers new drugs and ART strategies, the global funding crisis, cure-related research, key populations including transgender people and community concerns including chemsex.
Lenacapavir PURPOSE-1 and -2 studies show continued high efficacy as PrEP.
All reports
Subscribe to HTB by email to receive the latest news every 3-4 weeks.
Reports will also be posted to social media.
Twitter (X) – Bluesky – Facebook – Instagram